Who Paid My Doc
Mark Samonte
Anatomic Pathology & Clinical Pathology Montebello, CA Medical Doctor
NPI 1114140233 CMS profile 651324
101 E Beverly Blvd Ste 100A, Montebello, CA 90640
General payments
$40
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Mark Samonte of Montebello, CA is reported in the CMS Open Payments database as having received $40 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 27th percentile of Anatomic Pathology & Clinical Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $40 | 2 |
Beside peers
- Mark Samonte
- Anatomic Pathology & Clinical Pathology median
- Middle half of Anatomic Pathology & Clinical Pathology
- National median
In program year 2025, general payments to Mark Samonte were reported at $0. Among 2,804 Anatomic Pathology & Clinical Pathology profiles paid that year, the median was $51 and the middle half received between $24 and $149.
Show as a table
| Year | Mark Samonte | Anatomic Pathology & Clinical Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $65 | $22–$150 | $163 |
| 2020 | $0 | $44 | $19–$144 | $114 |
| 2021 | $40 | $42 | $19–$142 | $132 |
| 2022 | $0 | $54 | $20–$140 | $149 |
| 2023 | $0 | $60 | $23–$157 | $160 |
| 2024 | $0 | $51 | $23–$145 | $164 |
| 2025 | $0 | $51 | $24–$149 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 321 drugsPart D claims
41,768
Drug cost
$2,771,991
Branded share of claims
19.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 799 | $309,089 | |
| Januvia Sitagliptin Phosphate | Brand | 348 | $131,026 | |
| Jardiance Empagliflozin | Brand | 251 | $113,615 | |
| Ozempic Semaglutide | Brand | 117 | $113,572 | |
| Zileuton Er Zileuton | Brand | 45 | $111,952 | |
| Ingrezza Valbenazine Tosylate | Brand | 13 | $87,681 | |
| Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate | Brand | 52 | $82,012 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 286 | $70,475 | |
| Xarelto Rivaroxaban | Brand | 152 | $69,754 | |
| Entresto Sacubitril/Valsartan | Brand | 124 | $57,822 |
The 10 drugs with the highest cost, of 321 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 25 billing codesPaid by Medicare
$2,110,111
Medicare patients
3,070
Services billed
28,913
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 60% | |
| Depression | 59% | |
| Ischemic heart disease | 55% | |
| Heart failure | 38% | |
| COPD | 36% | |
| Alzheimer's or dementia | 35% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Anatomic Pathology & Clinical Pathology in California
Serge Alexanian
Anatomic Pathology & Clinical Pathology · Los Angeles, CA
Brian Cone
Anatomic Pathology & Clinical Pathology · Los Angeles, CA
John Blaustein
Anatomic Pathology & Clinical Pathology · Santa Barbara, CA
Henry Tsai
Anatomic Pathology & Clinical Pathology · Huntington Beach, CA
Stewart Comer
Anatomic Pathology & Clinical Pathology · Santa Barbara, CA
Eric Vail
Anatomic Pathology & Clinical Pathology · West Hollywood, CA
Related records
Anatomic Pathology & Clinical Pathology in California
Practitioners in the same specialty and state, ranked by reported value.
All Anatomic Pathology & Clinical Pathology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.